Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins

Journal of Thoracic and Cardiovascular Surgery

Volumn 124, Issue 3, 2002, Pages 621-625

  Tsunemi, Koutaro ^a   Takai, Shinji ^a   Nishimoto, Masayoshi ^a   Yuda, Atsushi ^a   Jin, Denan ^a   Sakaguchi, Masato ^a   Sawada, Yoshihide ^a   Asada, Kunio ^a   Kondo, Keiichiro ^a   Sasaki, Shinjiro ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMASE INHIBITOR; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; ISCHEMIC HEART DISEASE; MICROVASCULARIZATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; SURGICAL TECHNIQUE; VASCULAR TISSUE; VEIN GRAFT;

EID: 0036738015     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2002.125164     Document Type: Article

References (30)

1. Shelton ME, Forman MB, Virmani R, Bajaj A, Stoney WS, Atkinson JB. A comparison of morphologic and angiographic findings in long-term internal mammary artery and saphenous vein bypass grafts. J Am Coll Cardiol. 1988;11:297-307.
2. Cameron AA, Green GE, Brogno DA, Thornton J. Internal thoracic artery grafts: 20 year clinical follow-up. J Am Coll Cardiol. 1995;25:188-92.
3. van Son JA, Falk V, Walther T, Smedts FM, Mohr FW. Low-grade intimal hyperplasia in internal mammary and right gastroepiploic arteries as bypass grafts. Ann Thorac Surg. 1997;63:706-8.
4. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg. 1985;89:248-58.
5. de Feyter PJ, van Suylen RJ, de Jaegere PP, Topol EJ, Serruys PW. Balloon angioplasty for the treatment of lesions in saphenous vein bypass grafts. J Am Coll Cardiol. 1993;21:1539-49.
6. Borland JA, Chester AH, Yacoub MH. The renin angiotensin system in bypass graft surgery. Curr Opin Cardiol. 2000;15:371-7.
7. Suma H. Arterial grafts in coronary bypass surgery. Ann Thorac Cardiovasc Surg. 1999;5:141-5.
8. Sato T, Isomura T, Suma H, Horii T, Kikuchi N. Coronary artery bypass grafting with gastroepiploic artery composite graft. Ann Thorac Surg. 2000;69:65-9.
9. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52:11-34.
10. Takai S, Jin D, Sakaguchi M, Miyazaki M. Chymase-dependent angiotensin II formation in human vascular tissue. Circulation. 1999;100:654-8.
11. Takai S, Shiota N, Kobayashi S, Matsumura E, Miyazaki M. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta. FEBS Lett. 1997;412:86-90.
12. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta. 2000; 1480:245-57.
13. Takai S, Shiota N, Yamamoto D, Okunishi H, Miyazaki M. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch. Life Sci. 1996;58:591-7.
14. Yuda A, Takai S, Jin D, Sawada Y, Nishimoto M, Matsuyama N, et al. Angiotensin II receptor antagonist. L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci. 2000;68:41-8.
15. Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S. et al. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 2000;467:141-4.
16. Nishimoto M, Takai S, Kim S, Jin D, Yuda A, Sakaguchi M, et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation. 2001;104:1274-9.
17. Oleksyszyn J, Powers JC. Amino acid and peptide phosphonate derivatives as specific inhibitors of serine peptidases. Methods Enzymol. 1994;244:423-41.
18. Craig SS, Schwartz LB. Human MCTC type of mast cell granule: the uncommon occurrence of discrete scrolls associated with focal absence of chymase. Lab Invest. 1990;63:581-5.
19. McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim Biophys Acta. 1995;1267:115-21.
20. Zhang S, Anderson DF, Bradding P, Coward WR, Baddeley SM, MacLeod JD, et al. Human mast cells express stem cell factor. J Pathol. 1998;186:59-66.
21. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991;88:904-10.
22. Kim S, Kawamura M, Wanibuchi H, Ohta K, Hamaguchi A, Omura T, et al. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation. 1995;92:88-95.
23. Tazawa S, Nakane T, Chiba S. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery. J Pharmacol Exp Ther. 1999;288:898-904.
24. Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, et al. Inhibitors of angiotensin converting enzyme prevent myointimal proliferation after vascular injury. Science. 1989;245:186-8.
25. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study. Circulation. 1992;86:100-10.
26. Roux SP, Clozel JP, Kuhn H. Cilazapril inhibits wall thickening of vein bypass graft in the rat. Hypertension. 1991;18(suppl 4):1143-6.
27. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, et al. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension. 1991;18(suppl 4):1170-6.
28. Miyazaki M, Shiota N, Sakonjo H, Takai S. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog. Jpn J Pharmacol. 1999;79:455-60.
29. Miyazaki M, Wada T, Shiota N, Takai S. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury. J Hum Hypertens. 1999;13(suppl 1):S21-5.
30. Nishimoto M, Takai S. Sawada Y, Yuda A, Kondo K, Yamada M, et al. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery. J Thorac Cardiovasc Surg. 2001;121:729-34.